JPS613065A - Measurement of antigen - Google Patents
Measurement of antigenInfo
- Publication number
- JPS613065A JPS613065A JP59123756A JP12375684A JPS613065A JP S613065 A JPS613065 A JP S613065A JP 59123756 A JP59123756 A JP 59123756A JP 12375684 A JP12375684 A JP 12375684A JP S613065 A JPS613065 A JP S613065A
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- polymer
- enzyme
- measured
- bond
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
【発明の詳細な説明】
(産業上の利用分野)
本発明は、飼えば血清、尿などに含壕れる抗原、すなわ
ち薬物あるいは各種疾患に由来する微量成分などを酵素
免疫測定法にょυ測定する方法に関するものである。[Detailed Description of the Invention] (Industrial Application Field) The present invention uses enzyme immunoassay to measure antigens contained in serum, urine, etc. when kept, such as trace components derived from drugs or various diseases. It is about the method.
(従来の技術)
酵素免疫測定法には種々の方法が知られておシ、そのひ
とつに測定対象と同じ抗原に酵素基質を結合させ、これ
に抗体及びこの結合を分解する酵素を反応させて分解物
を抗原の/グナルとして測定する方法が知られている(
C1in Chem、、 23/8 。(Prior art) Various methods are known for enzyme immunoassay, one of which involves binding an enzyme substrate to the same antigen as the measurement target, and reacting this with an antibody and an enzyme that breaks down this bond. There is a known method for measuring degradation products as antigens (
C1in Chem,, 23/8.
pp 1402−1408(1977))。pp. 1402-1408 (1977)).
(発明が解決しようとする問題点)
この方法には、分解物の量が少ないため感度が低いとい
う問題点があった。(Problems to be Solved by the Invention) This method has a problem in that the sensitivity is low because the amount of decomposed products is small.
(問題点を解決するだめの手段)
本発明者らは、特定の酵素基質の重合体とこの″ −
−)
重合体を末端から切断する酵素を新たに加えることによ
り抗原を非常に高感度でしかも簡便に抗原を測定できる
ことを見出し、こ・の知見に基いて本発明を完成するに
至った。(Another means to solve the problem) The present inventors have developed a polymer of a specific enzyme substrate and this
-) We have discovered that antigens can be measured easily and with very high sensitivity by newly adding an enzyme that cleaves polymers from the ends, and based on this knowledge, we have completed the present invention.
すなわち、本発明は、測定対象の抗原と、該抗原と共通
の抗原決定基を有する物質と重合体の結合物を前記の共
通の抗原決定基と反応する抗体に接触せしめ、さらに該
結合物の抗原決定基を有する物質と重合体との間を切断
する酵素及び該重合体を末端から切断する酵素を作用せ
しめることを特徴とする抗原の測定方法に関するもので
ある。That is, in the present invention, a combination of an antigen to be measured, a substance having a common antigenic determinant with the antigen, and a polymer is brought into contact with an antibody that reacts with the common antigenic determinant, and further The present invention relates to a method for measuring an antigen, which comprises using an enzyme that cleaves between a substance having an antigenic determinant and a polymer, and an enzyme that cleaves the polymer from its terminal.
測定対象の抗原は特に制限されないが、本発明の方法に
は分イ量1万以下のものが特に好適である。このような
抗原の例としてノコゞキシン、テオフィリンなどの薬物
、ステロイドホルモン類、インシーリンなどを挙げるこ
とができる。高置9の抗原、例えばフェリチン、α−フ
エトフ0ロチインなどはプロテアーゼなどで分解し、あ
るいは合成ペプチド抗原として低分子化して必要により
抗原決定基部分を分離して測定できる。従って、HD抗
原、CA 19−9などのガン抗原、1−IBウィルス
、HB 、ヘルペスウィルス等のウィルス抗原、フィ
ブリン分解生成物、イムノグロブリン等の血漿蛋白等の
高分子抗原も本発明の方法て測定することができる。The antigen to be measured is not particularly limited, but antigens with a volume of 10,000 or less are particularly suitable for the method of the present invention. Examples of such antigens include drugs such as nocoxin and theophylline, steroid hormones, and incilin. High-altitude antigens, such as ferritin and α-fethoflotine, can be degraded with protease or the like, or reduced in molecular weight as synthetic peptide antigens, and if necessary, the antigenic determinant portion can be separated and measured. Therefore, polymer antigens such as HD antigens, cancer antigens such as CA 19-9, viral antigens such as 1-IB virus, HB, and herpes virus, plasma proteins such as fibrin degradation products, and immunoglobulins can also be used in the method of the present invention. can be measured.
後述する重合体と結合させる物質(以下、りがンドとい
う。)は測定対象の抗原と共通の抗原決定基をもするも
のである。抗原決定基は少なくともひとつが共通であれ
ばよく、全てが共通であってもよい。従って、リガンド
は測定対象の抗原と同一であってもよい。The substance to be bound to the polymer described below (hereinafter referred to as a ligand) also has a common antigenic determinant with the antigen to be measured. At least one antigenic determinant may be common, or all antigenic determinants may be common. Therefore, the ligand may be the same as the antigen to be measured.
重合体はアミノ酸、糖、エチレンオキサイド、ビニルア
ルコール、リン酸、ヌクレオチドなどの重合体である。The polymer is a polymer of amino acids, sugars, ethylene oxide, vinyl alcohol, phosphoric acid, nucleotides, etc.
アミノ酸の重合体は、例えばL−チロシン重合体、L−
トリシトファン重合体、L−フェニルアラニン重合体、
L−リジン重合体、L−グルタミン酸重合体、各種アミ
ノ酸よりなる天然のペプチドなどである。糖の重合体は
例えばグルコースのα−1,6結合重合体、β−ガラク
ト/ド重合体、デキストラン等である。エチレンオキサ
イドの重合体とはポリエチレングリコールであり、ビニ
ルアルコールの重合体とはポリビニルアルコールである
。リン酸の重合体はポリリン酸、ヘキサメタリン酸など
である。ヌクレオチドの重合体はポリアデニン、ポリグ
アニア、ポリント/ン、ポリチミン、各種ヌクレオチド
よりなる天然のポリヌクレオチドなどである。Examples of amino acid polymers include L-tyrosine polymers, L-
tricytophane polymer, L-phenylalanine polymer,
These include L-lysine polymers, L-glutamic acid polymers, and natural peptides made of various amino acids. Examples of sugar polymers include α-1,6-linked glucose polymers, β-galacto/depolymers, and dextran. The ethylene oxide polymer is polyethylene glycol, and the vinyl alcohol polymer is polyvinyl alcohol. Phosphoric acid polymers include polyphosphoric acid and hexametaphosphoric acid. Polymers of nucleotides include polyadenine, polyguania, polytin, polythymine, and natural polynucleotides composed of various nucleotides.
これらの重合体の重合度は二量体以上であり、特に制限
されないが、通常10〜10000分子程度が重合され
たものが好塘しい。The degree of polymerization of these polymers is not less than dimer, and is not particularly limited, but it is usually preferable that about 10 to 10,000 molecules are polymerized.
リガンドと重合体の結合方法はこの結合の切断に使用さ
れる酵素の種類によって異なる。The method of binding the ligand to the polymer varies depending on the type of enzyme used to cleave this bond.
ψりえはエステラーゼを使用する場合には、カルボキシ
ル基と水酸基を結合させる。リガンド側がカルボキシル
基の場合には、りがンドがぽゾチドであれば、カルボキ
シル基端あるいはグルタミン酸残基、アスパラギン酸残
基などを利用すればよい。りがンドがその他のものであ
ってカルボキシル基がない場合には、水酸基、ノ・ロゲ
ン、アミン基、アルデヒド基などを公知の方法でカルボ
キシル基に変えてこれを利用すればよい。重合体側の水
酸基には重合体が水酸基を有していればそれを利用すれ
ばよく、一方、ない場合には、ハロゲン、アルデヒド基
、カルボキシル基、カルボニル基、アミ7基などを公知
の方法により水酸基に変えてこれを利用すればよい。リ
ガンド側が水酸基で重合体側がカルボキシル基の場合も
同様でおる。カルボキシル基と水酸基の結合方法は活性
化エステル法、酸クロリド法、あるいはカルボッイミド
などの無水化剤を作用させる方法を利用すればよい。When using esterase, ψrie combines a carboxyl group and a hydroxyl group. When the ligand side is a carboxyl group, if the ligand is pozotide, the carboxyl end, glutamic acid residue, aspartic acid residue, etc. may be used. When the ligand is other and does not have a carboxyl group, a hydroxyl group, a nitrogen group, an amine group, an aldehyde group, etc. may be converted into a carboxyl group by a known method and used. If the polymer has a hydroxyl group, it may be used as the hydroxyl group on the polymer side.If the polymer does not have a hydroxyl group, a halogen, an aldehyde group, a carboxyl group, a carbonyl group, an amide group, etc. can be added using a known method. This can be used instead of a hydroxyl group. The same applies when the ligand side is a hydroxyl group and the polymer side is a carboxyl group. As a method for bonding carboxyl groups and hydroxyl groups, an activated ester method, an acid chloride method, or a method using an anhydrating agent such as carboimide may be used.
壕だ、ベゾチダーゼを使用する場合には、アミン基とカ
ルボキシル基の組合せが得られるように必要によりこれ
らの官能基をリガンド又は重合体側に適宜導入してから
公知被ゾチド合成法によりこれらを結合させればよい。However, when using bezotidase, these functional groups are introduced into the ligand or polymer side as necessary to obtain a combination of amine groups and carboxyl groups, and then these are bonded using known bezotide synthesis methods. That's fine.
また、この場合、アミノ酸重合体を利用するときには、
この重合体はリガンドに1ず1分イのアミノ酸を結合さ
せて、これにアミノ酸をRプチド結合法で次々と結合さ
せて重合体を形成させることもできる。In addition, in this case, when using an amino acid polymer,
This polymer can also be formed by bonding amino acids one by one to a ligand, and then bonding amino acids one after another to this using the R peptide bonding method.
他の酵素を利用する場合にも、その酵素に応じて適当な
官能基を選択し、これを公知の方法で結合ζせればよい
。When using other enzymes, appropriate functional groups may be selected depending on the enzyme and bonded using known methods.
共通の抗原決定基と反応する抗体は公知の方法に準じて
製造することができる。すなわち、抗原リガンド又はこ
れらと蛋白の結合物を兎、山羊、馬、モルモット、ニワ
トリなどの温血動物に体重1 kgあたり03〜2m9
を1〜数回背中皮下、フットパッド、大腿筋等にアジュ
バントとともに注射して当該動物の体内に形成させる。Antibodies that react with common antigenic determinants can be produced according to known methods. That is, antigen ligands or conjugates of these and proteins are administered to warm-blooded animals such as rabbits, goats, horses, guinea pigs, and chickens at doses of 0.3 to 2 m9 per 1 kg of body weight.
is injected subcutaneously into the back, foot pads, thigh muscles, etc. together with an adjuvant one to several times to form in the animal's body.
この抗体は血清をその寸ま用いてもよく、血清から抗体
すなわち免疫グロブリンを採取する公知の方法によって
精製してから用いてもよい。For this antibody, serum may be used as it is, or it may be used after being purified by a known method for collecting antibodies, ie, immunoglobulin, from serum.
一方、この抗体はモノクローナル抗体として取得するこ
ともできる。その場合には、マウスに前記のいずれかの
抗原゛をアソユパントとともに数回腹腔等に注射し、肺
臓細胞を取り出してポリエチレングリコール等を用いて
マウスミエローマ細胞と融合させる。そして、この融合
細胞のなかから当該抗体を産生ずるものをクローニング
によってモノクローン細胞として増殖させ、マウス腹腔
中で増殖させることによって単一抗体、すなわちモノク
ローナル抗体を大量に製造することができる。On the other hand, this antibody can also be obtained as a monoclonal antibody. In that case, one of the antigens mentioned above is injected into the peritoneal cavity of the mouse together with an associate several times, and the lung cells are taken out and fused with mouse myeloma cells using polyethylene glycol or the like. Then, by cloning those fused cells that produce the antibody, they are grown as monoclonal cells and grown in the peritoneal cavity of a mouse, thereby making it possible to produce a single antibody, that is, a monoclonal antibody in large quantities.
この抗体にはF(ab’)、、 + Fab’ 、 F
abなとのフラグメントも含まれる。This antibody has F(ab'), + Fab', F
Fragments with ab are also included.
測定対象の抗原と前記の結合物にこの抗体を接触させる
順序は問うところではなく、いずれが先であってもよい
が、特別の目的がなければ両方を一緒に加えればよい。The order in which this antibody is brought into contact with the antigen to be measured and the above-mentioned conjugate is not critical, and either may come first, but unless there is a particular purpose, both may be added together.
この抗原抗体反応をさせる溶液のPH及び温度は要は反
応しやすい条件に保てばよく、通常pH4,5〜105
で20〜45℃程度にあればよい。反応時間は通常は充
分に抗原抗体反応する程度がよく、5〜30分間程度で
よい。The pH and temperature of the solution that causes this antigen-antibody reaction should be kept under conditions that facilitate the reaction, usually pH 4.5 to 105.
The temperature should be about 20 to 45°C. The reaction time is usually sufficient to allow a sufficient antigen-antibody reaction, and may be about 5 to 30 minutes.
結合物のリガンドと重合物の間を切断する酵素はこの結
合の種類に応じて適当なものが選択され、例えばエステ
ラーゼ、ペプチダーゼ、リパーセ、コリンエステラーゼ
、ガラクトシダーゼ、グルコンダーゼなどを利用できる
。The enzyme that cleaves between the ligand of the conjugate and the polymer is selected appropriately depending on the type of bond, and for example, esterase, peptidase, lipase, cholinesterase, galactosidase, glucondase, etc. can be used.
重合物を末端から切断する酵素は、重合体の種類に応じ
、カルボキシ−!!ブチダーゼA1カルデキシベゾチダ
ーゼB1グルコアミラーゼ、プリエチレングリコールオ
キシダーゼ、ポリビニルアルコールオキシダーゼ、ポリ
ホスファターゼ、エキノヌクレオチダーゼなどを利用す
ればよい。Depending on the type of polymer, the enzyme that cleaves the polymer from the terminal is carboxy-! ! Butidase A1 caldexybezotidase B1 glucoamylase, polyethylene glycol oxidase, polyvinyl alcohol oxidase, polyphosphatase, echinonucleotidase, etc. may be used.
これらの酵素は前述の抗原抗体反応の終了後に添加して
もよく、壕だ、すべての試薬を一度に投入して抗原抗体
反応と酵素反応を並行して行なわせてもよい。各酵素反
応も同時に行なわせてもよく、別々に行なわせてもよい
。別個に行なわせる場合にはいずれの酵素反応が先であ
ってもよい。These enzymes may be added after the above-mentioned antigen-antibody reaction is completed, or all reagents may be added at once to allow the antigen-antibody reaction and the enzyme reaction to occur in parallel. Each enzymatic reaction may be performed simultaneously or separately. When carried out separately, either enzyme reaction may occur first.
酵素反応を速かに行なわせるために各酵素の使用量はな
るべく多くすることが好捷しい。各酵素反応は酵素の作
用しやすい条件下で行なわせるのが好ましいことはいう
壕でもなく、従って各酵素に応じて適当な温度、PH等
が設定される。In order to speed up the enzymatic reaction, it is preferable to use as much amount of each enzyme as possible. It is not necessarily the case that each enzymatic reaction is preferably carried out under conditions in which the enzyme is likely to act; therefore, appropriate temperature, pH, etc. are set depending on each enzyme.
分解物の測定方法は重合体の種類に応じて適当な方法が
選択され、例えばアミノ酸の場合には、ニンヒドリンを
用いて比色定量する方法、アミノ酸オキンダーゼで酸化
して生成するH2O2を酵素法あるいは化学的方法によ
り比色定量あるいは螢光分析法で定量する方法などで定
量することができる。このほか、チロンンが遊離する場
合にはヂロシナーゼを用いて共役酵素系で測定すること
もできる。Appropriate methods are selected to measure the decomposed products depending on the type of polymer; for example, in the case of amino acids, colorimetric determination using ninhydrin, enzymatic method using H2O2 produced by oxidation with amino acid okindase, or It can be quantified by chemical methods such as colorimetric determination or fluorescence analysis. In addition, when thironne is released, it can also be measured using a coupled enzyme system using dirosinase.
重合体が糖の場合には、例えば分解生成物がグルコース
であればグルコースオキンダーゼを作用させ、生成する
H2C。を化学発光させてもよく、あるいはフェノール
、ノξ−オギンダーゼ及び4−アミノアンチピリンを使
用して酸化縮合させ生成するキノンイミン色素を比色定
量してもよい。そのほか、02電極で測定することもで
きる。When the polymer is sugar, for example, if the decomposition product is glucose, H2C is produced by the action of glucose okindase. may be chemiluminescent, or the quinone imine dye produced by oxidative condensation using phenol, no-ξ-ogindase and 4-aminoantipyrine may be colorimetrically determined. In addition, measurement can also be performed using the 02 electrode.
重合体がポリエチレングリコールの場合には、ポリエチ
レングリコールオキシダーゼを作用させて2,5−ノク
ロロフェノールインドフェノールを酸化させ、これによ
り生ずる色素を比色定量すればよい。ポリビニルアルコ
ールの場合には、ポリビニルアルコールオキシダーゼで
酸化して生シルH2O2を常法により定量すればよい。When the polymer is polyethylene glycol, 2,5-nochlorophenolindophenol may be oxidized by the action of polyethylene glycol oxidase, and the resulting dye may be determined colorimetrically. In the case of polyvinyl alcohol, it may be oxidized with polyvinyl alcohol oxidase and raw sil H2O2 may be determined by a conventional method.
ポリリン酸の場合は、モリブデン酸法あるいは酵素的測
定法により定量できる。In the case of polyphosphoric acid, it can be quantified by the molybdate method or enzymatic measurement method.
分解物の測定方法はこれらに限定されるものではなく、
公知の各種方法のなかから適宜選択すればよい。The methods for measuring decomposition products are not limited to these.
The method may be appropriately selected from among various known methods.
(作用)
本発明の方法においては、測定対象の抗原と結合物中の
リガンドを抗体に対して競争反応させている。その場合
、測定対象の抗原が抗体に優先的に結合するところから
、結合物のりガツトが抗体と反応する量は試料中の抗原
の量に依存する。抗体と反応した結合物は立体障害等に
より酵素と反応しにくくなり、抗体と未反応の結合物が
酵素によって優先的に分解される。(Function) In the method of the present invention, the antigen to be measured and the ligand in the bound substance are caused to react competitively with the antibody. In this case, since the antigen to be measured preferentially binds to the antibody, the amount of the bound compound that reacts with the antibody depends on the amount of antigen in the sample. The conjugate that has reacted with the antibody becomes difficult to react with the enzyme due to steric hindrance, and the conjugate that has not reacted with the antibody is preferentially degraded by the enzyme.
(発明の効果)
本発明の方法においては1分子の結合物から複数のング
ナル物質を生成することから、抗原を高感度で1l11
定できる。壕だ、反応に必要な試薬類は一時に投入でき
ることから、操作も簡単であり、臨床分析法としてもす
ぐれている。(Effects of the Invention) Since the method of the present invention generates a plurality of gunar substances from one molecule of conjugate, antigens can be detected at 1l11 with high sensitivity.
Can be determined. Since the reagents necessary for the reaction can be added all at once, it is easy to operate and is an excellent clinical analysis method.
(実施ψ11)
カルボキシテオフィリ7100〜をDMF 2 meに
溶かし、塩化チオニル100μlを0℃て加えて4℃で
3時間続いて室温て1時間反応させた。こ′!1にモノ
メトキシポリエチし・ングリコール4000 を50m
9加えて室温で16時間反応させた。反応液をセファデ
ックスG−25のカラムに流し、20mM ’Jン酸緩
衝生理食塩溶液pH6,5で展開して未反応のテオフィ
リンを除去してテオフィリン−ポリエチレングリコール
結合物を得た。(Implementation ψ11) Carboxytheophyllin 7100 ~ was dissolved in DMF 2 me, 100 μl of thionyl chloride was added at 0° C., and the mixture was reacted at 4° C. for 3 hours and then at room temperature for 1 hour. child'! Add 50 m of monomethoxy polyethyl glycol 4000 to 1.
9 and reacted at room temperature for 16 hours. The reaction solution was applied to a Sephadex G-25 column and developed with 20mM 'J acid buffered saline solution pH 6.5 to remove unreacted theophylline to obtain a theophylline-polyethylene glycol conjugate.
テオフィリンO〜50μgを含む血清者50μlに上記
の結合物250 tt9を含む溶液を1001Alづつ
加え、さらに抗テオフィリンマウスIgG1〜を含有す
る溶液100μlを加えて37℃で20分間反応させた
。次に、カルピギシエステシーゼ2000UA/X、t
?リエチレングリコールオキシダーセ°4000UAl
及びノクロロフェノールインドフエノール0.01mM
を含む溶液3mlを加えて37℃で30分間反応させ、
反応液の580 nmにおける吸光度を測定した。得ら
れた結果を図面に示す。To 50 μl of serum sample containing 50 μg of theophylline O, 1001 Al portions of the solution containing the above conjugate 250 tt9 was added, and further 100 μl of a solution containing anti-theophylline mouse IgG1 was added, followed by reaction at 37° C. for 20 minutes. Next, Carpigysis Esthesis 2000UA/X, t
? Liethylene glycol oxidase °4000UAl
and nochlorophenol indophenol 0.01mM
Add 3 ml of a solution containing and react at 37°C for 30 minutes,
The absorbance of the reaction solution at 580 nm was measured. The results obtained are shown in the drawings.
次に、各種血清について上記と同様にして測定し、図面
の曲線を検量線に用いてテオフィリン濃度を求めた結果
を下表に示す。なお、同じ血清について従来法であるラ
ジオイムノア、セイ(RIA)で測定した結果も併ぜで
同表に示す。Next, various serums were measured in the same manner as above, and the theophylline concentration was determined using the curve in the drawing as a calibration curve. The results are shown in the table below. The same table also shows the results of measuring the same serum using a conventional method, Radioimmunoa, Sei (RIA).
テオフィリン濃度(μ!17m(’)
A 2.1 1.
6B 4.5 4
.3C10,110,6
D I8,5 16.
9E 1.2 1
.0F 23.1 2
2.5G 31 2
9.4Theophylline concentration (μ!17m(') A 2.1 1.
6B 4.5 4
.. 3C10,110,6 D I8,5 16.
9E 1.2 1
.. 0F 23.1 2
2.5G 31 2
9.4
図面は血清中のテオフィリン濃度と吸光度の関係の一例
を示すものである。
特許出願人 富士レビオ株式会社
代 理 人 弁理士 1)中 政 浩0 +
、4 16 64 256 +000pg/mlThe drawing shows an example of the relationship between theophylline concentration in serum and absorbance. Patent applicant Fujirebio Co., Ltd. Representative Patent attorney 1) Masahiro Naka 0 +
, 4 16 64 256 +000pg/ml
Claims (2)
有する物質と重合体の結合物を前記の共通の抗原決定基
と反応する抗体に接触せしめ、さらに該結合物の抗原決
定基を有する物質と重合体との間の結合を切断する酵素
及び該重合体を末端から切断する酵素を作用せしめるこ
とを特徴とする抗原の測定方法(1) A combination of an antigen to be measured and a substance and a polymer having a common antigenic determinant with the antigen is brought into contact with an antibody that reacts with the common antigenic determinant, and further the antigenic determinant of the combination is A method for measuring an antigen, which comprises causing an enzyme to cleave a bond between a substance having a substance and a polymer, and an enzyme to cleave the polymer from the end to act.
の抗原の測定方法(2) The method for measuring an antigen according to claim 1, wherein the polymer is a dimer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP59123756A JPS613065A (en) | 1984-06-18 | 1984-06-18 | Measurement of antigen |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP59123756A JPS613065A (en) | 1984-06-18 | 1984-06-18 | Measurement of antigen |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS613065A true JPS613065A (en) | 1986-01-09 |
JPH0317301B2 JPH0317301B2 (en) | 1991-03-07 |
Family
ID=14868521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP59123756A Granted JPS613065A (en) | 1984-06-18 | 1984-06-18 | Measurement of antigen |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS613065A (en) |
-
1984
- 1984-06-18 JP JP59123756A patent/JPS613065A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
JPH0317301B2 (en) | 1991-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1206877A (en) | Immunoassay for nonenzymatically glucosylated proteins and protein fragments - an index of glycemia | |
EP0094777B1 (en) | Biologically active composition and immunoassay using the same | |
US6114180A (en) | Synthetic calibrators for use in immunoassays, comprising the analytes or partial sequences thereof which are conjugated to inert carrier molecules | |
CN1047666C (en) | Antibodies and mehod for their use | |
CA2162568C (en) | Method and reagent for simultaneously assaying one or more ligands in a group of preselected ligands | |
JPS58203919A (en) | Manufacture of immunogloblin half molecule and crossbred antibody | |
US20120214187A1 (en) | Method for Enhancing the Sensitivity of Antibody Based Assays | |
JPS61502417A (en) | Polyclonal antibodies, manufacturing method and uses | |
US6331402B1 (en) | Reduction of interference of immunoassays by substances derived from the framework regions of antibodies | |
JP4130505B2 (en) | Elimination of diagnostic method interference by peptides consisting of D-amino acids | |
AU595159B2 (en) | Bispecific antibody determinants | |
US5792606A (en) | Nucleic acid hybridization based assay for determining a substance of interest | |
Fujiwara et al. | Preparation of polyamine antibody and its use in enzyme immunoassay of spermine and spermidine with β-D-galactosidase as a label | |
CN102183635A (en) | In vitro detection kit for TAFI content | |
CA1194415A (en) | Immunoglobulin half-molecules and process for producing hybrid antibodies | |
JPH06505340A (en) | Analytical reagent production method | |
CN102103142A (en) | In-vitro assay method for thrombin-activatable fibrinolysis inhibitor (TAFI) content | |
JPH05508770A (en) | Pancreatic elastase 1-specific antibody, method for obtaining the same, and test kit containing the antibody | |
JPS613065A (en) | Measurement of antigen | |
JP2994739B2 (en) | Rapid measurement of trace components | |
JPH0566223A (en) | Measuring method for large amount of analyzed material | |
JP2509840B2 (en) | Immunoassay method and immunoassay reagent kit | |
JP2518602B2 (en) | Immunological assay reagent and kit using monoclonal antibody against human protein S | |
JP3166764B2 (en) | Rapid measurement of trace components | |
EP0228810A1 (en) | Enzyme immunoassay method for epidermal growth factor |